331 filings
10-Q
2024 Q1
FENC
Fennec Pharmaceuticals Inc
Quarterly report
14 May 24
5:24pm
DEF 14A
FENC
Fennec Pharmaceuticals Inc
Definitive proxy
13 May 24
4:42pm
8-K
FENC
Fennec Pharmaceuticals Inc
8 May 24
Other Events
8:29pm
10-K
2023 FY
FENC
Fennec Pharmaceuticals Inc
Annual report
29 Mar 24
4:14pm
8-K
FENC
Fennec Pharmaceuticals Inc
25 Mar 24
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
4:05pm
8-K
2szsx pgc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
424B7
l536onhz9h
15 Mar 24
Prospectus with selling stockholder info
3:53pm
8-K/A
bmt6fp7ubo0
6 Mar 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:07pm
8-K
6clwfx51y ky
29 Feb 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
4:04pm
8-K
b2mnuvj5eetthxmqg5
2 Feb 24
FDA Issues Reminder of Non-Substitution of PEDMARKÒ (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
12:00am
EFFECT
gtvrkxmct
18 Dec 23
Notice of effectiveness
12:15am
CORRESP
f30v768u9 kub7vl4
13 Dec 23
Correspondence with SEC
12:00am
8-K
qi4 9ft3mv
5 Dec 23
Fennec Announces Incremental $5 Million Investment from Petrichor
8:51pm
UPLOAD
u958wrr
28 Nov 23
Letter from SEC
12:00am
8-K
5n6tasr074i 76i2v8jn
6 Nov 23
Fennec Pharmaceuticals Announces Third Quarter 2023
7:38pm
8-K/A
xkrdzb1yut9ac
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K
vha5 wrdwqh
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am